Updated Interim Data from Clene Nanomedicine's RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Science Program at 2022 AAN Annual Meeting
SALT LAKE CITY, April 01, 2022 -- Clene Inc. along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical... | April 1, 2022
Source: marketscreener.com